Pay in 4 interest-free payments of $6.10 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
As of April 2026, Zepbound (tirzepatide) appears on the formulary with the following restrictions: Covered indications: Type 2 diabetes mellitus as an adjunct to diet and exercise Must be prescribed by a TRICARE-authorized provider Requires prior authorization regardless of plan type Subject to step therapy requirements (metformin, sulfonylureas, or other first-line agents must be tried first) Excluded indications: Obesity or weight management in patients without type 2 diabetes Overweight status (BMI 25 to 29.9) Metabolic syndrome without diagnosed diabetes Prediabetes (HbA1c 5.7% to 6.4%) Cardiovascular risk reduction in non-diabetic patients The distinction matters because Zepbound is FDA-approved for both chronic weight management (approved December 2023) and type 2 diabetes (approved May 2022 under the brand name Mounjaro)
940 TQCN treatment may improve numerous neurodegenerative diseases related with brain iron accumulation and ameliorate severe cognitive impairment in AD mice due to its multiplex modulation of the pathogenic process that triggers ferroptosis
Nausea associated with GLP-1 receptor agonists typically occurs because these medications delay the rate at which food leaves the stomach (gastric emptying)
Glutathione is a very important substance made from the amino acids like glycine, cysteine and glutamic acid
Stites W, Wang L, Gatlin DM III
US$ 27.76
US$ 21.20
US$ 28.81
US$ 21.31
